The purpose of this study is to evaluate the effect of pharmacogenetic (PGx) testing on
clinical outcomes in a group of subjects exhibiting neuropsychiatric disorders, such as
depression and anxiety, as compared to a group of subjects with the same attributes without
the guidance of PGx testing for their treatment.
This study will also evaluate whether pharmacogenetic (PGx) testing can reduce adverse drug
events, hospitalization rates, hospital length of stay, emergency room visits, disability,
death or other serious drug side effects.